Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials

Clinical Infectious Diseases

Volumn 63, Issue 11, 2016, Pages 1405-1411

  Grebely, Jason ^a   Mauss, Stefan ^b   Brown, Ashley ^c   Bronowicki, Jean Pierre ^d   Puoti, Massimo ^e   Wyles, David ^f   Natha, Macky ^g   Zhu, Yanni ^g   Yang, Junming ^g   Kreter, Bruce ^g   Brainard, Diana M ^g   Yun, Chohee ^g   Carr, Val ^h   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Center for HIV and Hepatogastroenterology   (Germany)

^c ST MARY S HOSPITAL   (United Kingdom)

^d INSERM   (France)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g GILEAD SCIENCES   (United States)

^h Gilead Sciences   (United Kingdom)

Author keywords

DAA; Drug use; Hepatitis C virus; Opioid substitution therapy; PWID

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CANNABINOID; COCAINE; ILLICIT DRUG; LEDIPASVIR PLUS SOFOSBUVIR; METHADONE; METHAMPHETAMINE; NALOXONE; OXYCODONE; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; BACKACHE; BODY MASS; CHRONIC HEPATITIS C; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; NAUSEA; OPIATE SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; PERSONALITY DISORDER; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; RASH; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DATA INTERPRETATION, STATISTICAL; DRUG THERAPY, COMBINATION; DRUG USERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; RETROSPECTIVE STUDIES; RIBAVIRIN; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; VIRAL LOAD;

EID: 85014883231     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw580     Document Type: Article

References (26)

1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10:553-62.
2. Suryaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis 2014; 59:1411-9.
3. Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 2012; 107:1318-27.
4. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis 2013; 57(suppl 2): S32-8.
5. Grebely J, Robaeys G, Bruggmann P, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy 2015; 26:1028-38.
6. Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013; 58:1598-609.
7. Larney S, Grebely J, Hickman M, De Angelis D, Dore GJ, Degenhardt L. Defining populations and injecting parameters among people who inject drugs: implications for the assessment of hepatitis C treatment programs. Int J Drug Policy 2015; 26:950-7.
8. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49:561-73.
9. Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013; 57(suppl 2):S80-9.
10. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2013; 56:806-16.
11. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015; 163:215-23.
12. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55:245-64.
13. Robaeys G, Grebely J, Mauss S, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis 2013; 57(suppl 2):S129-37.
14. AASLD/IDSA. Recommendations for testing, managing, and treating hepatitis C. Available at: www.hcvguidelines.org. Accessed 18 January.
15. WHO. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva, Switzerland: World Health Organization, 2014.
16. Martin NK, Vickerman P, Dore GJ, et al. Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J Hepatol 2016; 65:17-25.
17. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-98.
18. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-93.
19. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879-88.
20. Grebely J, Matthews GV, Hellard M, et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol 2011; 55:76-85.
21. Lalezari J, Sullivan JG, Varunok P, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol 2015; 63:364-9.
22. Dore GJ, Altice F, Litwin AH, et al. Elbasvir/grazoprevir to treat HCV infection in persons receiving opioid agonist therapy: a randomized controlled trial (C-EDGE CO-STAR). Ann Intern Med 2016; doi:10.7326/M16-0816.
23. 4th International Symposium on Hepatitis Care in Substance Users, Sydney, Australia, 7-9 October 2016.
24. Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 2016; 62:683-94.
25. Cunningham EB, Applegate TL, Lloyd AR, Dore GJ, Grebely J. Mixed HCV infection and reinfection in people who inject drugs-impact on therapy. Nat Rev Gastroenterol Hepatol 2015; 12:218-30.
26. Grebely J, Haire B, Taylor LE, et al. Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data? J Hepatol 2015; 63:779-82.